

## Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY No. 2019-428-A 23 JUL 2021

TO:

ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC

SUBJECT:

Lifting the Advisory of the following Registered Food Supplements under FDA Advisory no. 2019-428 Subject "Public Health Warning Against the Purchase and Consumption of the Unregistered Food Supplements"

- 1. HERBS OF THE EARTH BONE + VITAMINS + MINERALS + HERBAL PROPRIETARY BLEND DIETARY SUPPLEMENT
- 2. HERBS OF THE EARTH L-LYSINE+ DIETARY SUPPLEMENT TABLET

The Food and Drug Administration (FDA) informs the public that the following food supplements are now registered by the Market Authorization Holder, **ECO ELEMENTS INC**. in accordance to existing FDA rules and regulations.



Figure 1. The Approved label of HERBS OF THE EARTH BONE + Vitamins + Minerals + Herbal Proprietary Blend Dietary Supplement, 90 Tablet with registration number FR-4000005553545 valid until 06 March 2022.

Civic Drive, Filinvest Corporate City, Alabang 1781 Muntinlupa, Philippines
Trunk Line +63 2 857 1900
Fax +63 2 807 0751
Website: www.fda.gov.ph
Email: info@fda.gov.ph



Management System ISO 9001:2015





Figure 2. The Approved label of HERBS OF THE EARTH L-Lysine+ Dietary Supplement Tablet with registration number FR-4000005993857 valid until 02 June 2022.

Accordingly, the list released in FDA Advisory No. 2019-428 is hereby updated to remove the aforementioned food supplements.

The public is advised to always check if a food product or food supplement is registered with the FDA by using the FDA Verification Portal feature accessible at <a href="https://verification.fda.gov.ph">https://verification.fda.gov.ph</a>. You may also look for the FDA Registration number on the product label, if available or simply type the name of the product.

To report any sale or distribution of unregistered food product, kindly email us through <a href="mailto:ereport@fda.gov.ph">ereport@fda.gov.ph</a>.

The public health warning imposed on the remaining products listed in FDA Advisory No. 2019-428 shall remain to be upheld and shall not be affected by the issuance of this advisory. Furthermore, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to the existing laws, rules, and regulations.

Dissemination of this advisory to all concerned is hereby requested.

ROLANDO ENRIQUE D. DOMINGO, MD
Director General

DTN 20201106112945